Roche personalized cancer treatment Rozlytrek priced at Rs 12 lakh per month

Rozlytrek was approved by the U.S. Food and Drug Administration on Thursday to treat certain types of solid tumours, which show rare genetic anomalies called NTRK fusions.

U.S: Roche Holding AG has priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, that targets tumours with specific genetic mutations, the Swiss drugmaker said.

The treatment will cost about $17,050 per month for adult patients, a company spokesman said on Friday. Rozlytrek will compete against German drugmaker Bayer AG's Vitrakvi, which is priced at $32,800 per month.

Rozlytrek was approved by the U.S. Food and Drug Administration on Thursday to treat certain types of solid tumours, which show rare genetic anomalies called NTRK fusions.

Read Also: Single dose of Xofluza flu drug as effective as Tamiflu in kids, says Roche

The treatment also won approval to treat adults with non-small cell lung cancer, whose tumours show genetic mutations called ROS1 fusions.

Vitrakvi, developed by Bayer in partnership with Eli Lilly and Co's Loxo Oncology, won the U.S. approved in November to treat patients with NTRK-positive solid tumours.

Read Also: Roche wins Japan approval for personalised cancer drug Rozlytrek